Insulet Corporation (NASDAQ:PODD) Just Reported, And Analysts Assigned A US$172 Price Target
Simply Wall St reports Insulet (PODD) shares fell 15% to about $141 after its latest quarterly results. Revenue was $802m in line with forecasts, while statutory profit was $1.37 per share. Analysts now expect 2026 revenue of $3.29b and EPS $6.17, with the consensus price target cut 27% to $172.
How this was made
The 30-second read
Why it matters
Analysts reportedly kept 2026 revenue and EPS forecasts steady but reduced the consensus price target to $172, implying valuation concerns after the latest results and the stock’s 15% weekly decline.
Market read
For traders, the actionable signal is the 27% consensus price-target reduction alongside unchanged forecast numbers, which can influence positioning and sentiment even without new guidance.
What to watch
The article does not detail the reasons behind the price-target reduction or any updated assumptions (e.g., margins, device demand, reimbursement), so the market may be overreacting to the target change alone.
Background
Simply Wall St summarizes post-earnings consensus forecasts for Insulet and compares them to prior estimates and industry growth expectations.
Ticker impact
Insulet shares fell 15% after quarterly results, while analysts kept 2026 revenue/EPS forecasts but cut the consensus price target to $172.
Likely modest downside bias for PODD as traders react to the 27% target reduction, even without new guidance changes.
The newest concrete items are the 15% weekly drop, the statutory EPS beat, and the 27% consensus price-target cut; however, the body says revenue/EPS estimates were largely unchanged, limiting fundamental re-rating catalysts.
Market effects
No direct sector catalyst beyond a general expectation of slower revenue growth versus Insulet’s historical pace.
None specified.
None specified.
Counterpoint
The statutory EPS beat and unchanged 2026 revenue/EPS forecasts suggest the target cut may reflect valuation conservatism rather than deteriorating fundamentals.
Key entities
- companyInsulet Corporation
NASDAQ-listed medical device company; article focuses on post-earnings consensus forecasts and the consensus price-target cut.
